Cialis can help those with spinal-cord related impotence achieve erections adequate for intercourse up to 3 times more often than usual, according to a new study by French researchers into spinal cord injury patients. The drugs active ingredient tadalafil is manufactured by Lilly ICOS LLC and can help impotent men achieve an erection for up to 36 hours after taking Cialis.
Cialis study and results
The study researched into the effects of Cialis on men with erectile dysfunction after spinal injury and was conducted by researchers from the Raymond Poincare Hospital in Garches, France. It involved 197 men who were then divided into two groups, all of whom had some type of spinal cord injuries and mild erectile dysfunction. For the first 4 weeks of the study, no Cialis or placebo drugs were administered.
For the next 12 weeks, men were unknowingly assigned to either the Cialis group or the placebo pill group. It was advised that they take no more than 1 Cialis or placebo tablet a day prior to sexual activity.
After 4 months, an average of 75.4 percent of men taking Cialis were successful in achieving an adequate erection compared to just 41.1 percent of those who were in the placebo group. The most promising results were found in the percentage of men who were successful when attempting intercourse; 47.6 percent in the Cialis group compared to 16.8 percent in the placebo. This finding conclusively proves that Cialis can help men who suffer from impotence have sex almost 3 times more often compared to when not using any impotence drugs.
Cialis and the impotence drugs market
Cialis has made a huge impact on the erectile dysfunction drug market since it first arrived in Europe in February 2003. Cialis works in the same way as its main competitors, Levitra and Viagra, with the advantageous benefit of lasting up to 9 times longer.
Since its approval by the FDA for the United States in November 2003, Cialis has been steadily eating into the impotence drug market previously dominated by Pfizer’s Viagra. The impotence drug is a prescription only drug available in over 100 countries worldwide, holding a share of up to 40 percent of the market in some regions.
The research conducted by the Raymond Poincare Hospital in France was funded by Cialis manufacturer Lilly ICOS LLC and is due to be published in the November 2007 issue of the Archives of Neurology. The results also showed that there were minimal side effects experienced by those in the Cialis group hence providing great news for all men suffering from erectile dysfunction.
